Quest Group Intl - Series A preferred stock, $.001 par value,...

Quest Group Intl - Recent Material Event

Item 1.	Condensed Financial Statements
	Item 2.	Management’s Discussion and Analysis or Plan of Operation.
	Item 3.	Controls and Procedures

PART II	OTHER INFORMATION

	Item 1.	Legal Proceedings
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds
	Item 3.	Defaults Upon Senior Securities
	Item 4.	Submission of Matters to a Vote of Security Holders
	Item 5.	Other Information
	Item 6.	Exhibits.

SIGNATURES
EXHIBIT INDEX

PART I FINANCIAL INFORMATION

Item 1. Condensed Financial Statements

NuRx Pharmaceuticals, Inc.

(a corporation in the development stage)

Condensed Balance Sheets

As of June 30, 2008 and September 30, 2007


	June 30, 2008 (unaudited)			September 30, 2007
ASSETS

Cash and cash equivalents	$	12,420,964		$	14,941,723
Prepaid expenses and other current assets		107,161			55,832
Total current assets		12,528,125			14,997,555


Property & equipment, net of accumulated depreciation and amortization of $7,969 and $1,382		46,467			27,825

Deposits		42,093			27,093
Total assets	$	12,616,685		$	15,052,473


LIABILITIES AND STOCKHOLDERS' EQUITY

Accounts payable and accrued expenses	$	243,712		$	103,441
Due to related parties		48,333			36,090
Total current liabilities		292,045			139,531

Commitments and contingencies

Stockholders' Equity
Series A preferred stock, $.001 par value, 1,000,000 shares designated, no shares issued and outstanding		—			—

Series B preferred stock, $.001 par value, 500,000 shares designated, no shares issued and outstanding		—			—

Common stock, $.001 par value, 150,000,000 shares authorized, respectively, 30,333,984 and 28,577,252 shares issued respectively, and 28,394,234 and 26,637,502 shares outstanding respectively		30,334			28,577
Additional paid-in capital		22,319,859			18,552,888
Treasury stock		(750,000	)		(750,000	)
Accumulated deficit during development stage		(9,311,753	)		(2,954,723	)
Retained earnings		36,200			36,200

Total stockholders' equity		12,324,640			14,912,942

Total liabilities and stockholders' equity	$	12,616,685		$	15,052,473

See Notes to Condensed Financial Statements

NURX PHARMACEUTICALS, INC.

(a corporation in the development stage)

Condensed Statements of Operations (unaudited)

For the three and nine months ended June 30, 2008 and June 30, 2007, and

development stage from inception (May 1, 2007) through June 30, 2008

	Three months ended June 30						Nine months ended June 30						Inception (May 1, 2007) through June
													30, 2008

Operating Expenses:

General & administrative (includes stock based compensation of $86,089, $13,485, $202,897, $13,485, and $268,726, related party consulting fees of $100,000, $60,000, $287,500, $60,000, and $452,200 respectively)	$	782,403		$	263,256		$	2,047,133		$	263,256		$	2,865,729

Research & clinical development (includes stock based compensation of $43,882, $0, $52,831 , $0, and $52,831, related party consulting fees and salary of $88,333, $0, $195,064, $0 and $201,154 respectively, and fair value of shares issued in connection with milestone payment under technology license of $0, $2,150,000, $3,513,000, $2,150,000, and $3,513,000 respectively)		470,887			2,190,769			4,656,682			2,190,769			7,043,831
Total operating expenses		1,253,290			2,454,025			6,703,815			2,454,025			9,909,560

Other income and (expense)
Interest income		67,042			73,310			346,785			73,310			610,432
Interest expense		—			(12,625	)		—			(12,625	)		(12,625	)
Total other income		67,042			60,685			346,785			60,685			597,807

Loss from continuing operations		(1,186,248	)		(2,393,340	)		(6,357,030	)		(2,393,340	)		(9,311,753	)

Income (loss) from discontinued operations, net of income tax of $0, $0, $0, $0, and $0, respectively		—			(2,118	)		—			62,337			—
Loss on disposition of discontinued operations, net of income tax of $0, $0, $0, $0 and $0, respectively		—			(192,991	)		—			(192,991	)		—

Net Loss	$	(1,186,248	)	$	(2,588,449	)	$	(6,357,030	)	$	(2,523,994	)	$	(9,311,753